乳腺癌组织中Glut1蛋白表达及其临床意义

Expression of Glucose Transporter 1 in Human Breast Carcinoma and Its Clinical Significance

目的探讨乳腺癌组织中葡萄糖转运蛋白1(glucose transporter-1,Glut1)的表达及其与细胞增殖活性和临床病理因素的关系。方法采用免疫组织化学方法检测Glut1和增殖细胞核抗原(proliferating cell nuclearantigen,PCNA)在80例乳腺癌组织、20例乳腺纤维腺瘤及20例普通乳腺增生组织中的表达水平,并分析它们之间的相关性。结果Glut1在乳腺纤维腺瘤、普通乳腺增生组织中不表达;乳腺癌中Glut1阳性率58.8%(47/80),其中原位癌中阳性率45.0%(9/20),高分化浸润癌中50.0%(15/30),低分化浸润癌中76.7%(23/30);乳腺癌中PCNA阳性率75%(60/80),其中原位癌中65%(13/20),浸润癌中78.3%(47/60)。Glut1与PCNA呈显著正性相关(r=0.742,P<0.01)。Glut1在肿瘤大小、腋窝淋巴结转移、雌、孕激素受体状态及组织学分级中表达差异有统计学意义。结论Glut1蛋白过表达参与乳腺癌的发生、发展,与乳腺癌细胞增殖关系密切,可为不同治疗策略和判断预后提供依据,有望成为乳腺癌治疗新靶点。

Objective To investigate the expression of glucose transporter 1 （Glut1） in human breast cancer and its relationship to proliferating ceil nuclear antigen （PCNA） protein, other tumor biomarkers and clinical pathologic factors. Methods Imunohistochemical staining （SP） was applied to measure the expression of Glut1 and PCNA in 20 cases of human breast fibroadenoma, 20 cases of usual hyperplasia and 80 cases of breast carcinoma. Results Glut1 was not found expressing in breast fibroadenoma and hyperplastic lesions. In contrast, the total positive rate of Glut1 in breast carcinoma was 58.8% （47/80） ; that in the ductal carcinoma in situ （DCIS） was 45.0% （9/20）, that in the well-differentiated invasive carcinoma was 50.0%（15/30） and that in the poorly differentiated was 76.7% （23/30）. The total positive rate of PCNA in breast carcinoma was 75% （60/80）, that in DCIS was 65% （13/20） and that in invasive carcinoma was 78.3% （47/60）. There was a positive correlation between Glut1 and PCNA level （r=0. 742, P〈0.01）. Conclusion The overexpression of Glut1 play important roles in carcinogenesis and progression of breast carcinoma and closely correlate with cell proliferation of breast carcinoma, may suggest different therapeutic approaches or the need for closer follow-up, and be wished to become a new target for treatment of breast carcinoma.